Trastuzumab emtansine (T-DM1) vs trastuzumab (H) in Chinese patients (pts) with residual invasive disease after neoadjuvant chemotherapy for HER2-positive breast cancer (BC) in the phase III KATHERINE study

被引：0
|
作者：
Huang, C. [1 ,2 ]
Yang, Y. [3 ,4 ]
Kwong, A. [5 ]
Chen, S-C. [6 ]
Tseng, L-M. [7 ]
Liu, M-C. [8 ]
Shen, K. [9 ]
Wang, S. [10 ]
Ng, T-Y. [11 ]
Feng, Y. [12 ]
Sun, G. [12 ]
Yan, I. R. [12 ]
Shao, Z. [13 ]
机构：
[1] Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan
[2] Natl Taiwan Univ, Coll Med, Taipei, Taiwan
[3] China Med Univ, Taichung Vet Gen Hosp, Taipei, Taiwan
[4] China Med Univ, Sch Med, Taipei, Taiwan
[5] Univ Hong Kong, Queen Mary Hosp, Dept Surg, Hong Kong, Peoples R China
[6] Chang Gung Med Fdn, Div Gen Surg, Taipei, Taiwan
[7] Taipei Vet Gen Hosp, Dept Surg, Taipei, Taiwan
[8] Koo Fdn Sun Yat sen Canc Ctr, Oncol, Taipei, Taiwan
[9] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Shanghai, Peoples R China
[10] Sun Yat Sen Univ, Canc Ctr, Med Oncol, Guangdong Sheng, Peoples R China
[11] Tuen Mun Hosp, Clin Oncol, Hong Kong, Peoples R China
[12] Roche China Holding Ltd, PDO, Shanghai, Peoples R China
[13] Fudan Univ, Shanghai Canc Ctr, Breast Surg, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1O
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer
    Ponde, Noam
    Ameye, Lieveke
    Lambertini, Matteo
    Paesmans, Marianne
    Piccart, Martine
    de Azambuja, Evandro
    EUROPEAN JOURNAL OF CANCER, 2020, 126 : 65 - 73
  • [42] Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy
    Jain, Sarika
    Shah, Ami N.
    Santa-Maria, Cesar A.
    Siziopikou, Kalliopi
    Rademaker, Alfred
    Helenowski, Irene
    Cristofanilli, Massimo
    Gradishar, William J.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 171 (02) : 371 - 381
  • [43] Adjuvant Trastuzumab Emtansine (T-DM1) and Concurrent Radiotherapy for Residual Invasive HER2-positive Breast Cancer Single-center Preliminary Results
    Zolcsak, Zita
    Loirat, Delphine
    Fourquet, Alain
    Kirova, Youlia M.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2020, 43 (12): : 895 - 901
  • [44] Population pharmacokinetics of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced gastric cancer (AGC)
    Chen, Shang-Chiung
    Kaagedal, Matts
    Gao, Yuying
    Wang, Bei
    Harle-Yge, Marie-Laurence
    van der Horst, Tina
    Jin, Jin
    Girish, Sandhya
    Li, Chunze
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2016, 43 : S35 - S35
  • [45] The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer
    Delgado, J.
    Vleminckx, C.
    Sarac, S.
    Sosa, A.
    Bergh, J.
    Giuliani, R.
    Enzmann, H.
    Pignatti, F.
    ESMO OPEN, 2021, 6 (02)
  • [46] Subgroup analysis by disease history and prior treatments of patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC) from DESTINY-Breast03, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1)
    Cortes, J.
    Im, S-A.
    Iwata, H.
    Hamilton, E. P.
    Hurvitz, S. A.
    Egorov, A.
    Cathcart, J.
    Liu, Y.
    Bako, E.
    Curigliano, G.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S645 - S646
  • [47] Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer
    Ian E. Krop
    Shanu Modi
    Patricia M. LoRusso
    Mark Pegram
    Ellie Guardino
    Betsy Althaus
    Dan Lu
    Alexander Strasak
    Anthony Elias
    Breast Cancer Research, 18
  • [48] Drug Interaction Potential of Trastuzumab Emtansine (T-DM1) Combined with Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
    Lu, Dan
    Burris, Howard A., III
    Wang, Bei
    Dees, E. Claire
    Cortes, Javier
    Joshi, Amita
    Gupta, Manish
    Yi, Joo-Hee
    Chu, Yu-Waye
    Shih, Ted
    Fang, Liang
    Girish, Sandhya
    CURRENT DRUG METABOLISM, 2012, 13 (07) : 911 - 922
  • [49] Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study
    Cortes, J.
    Kim, S-B.
    Chung, W-P.
    Im, S-A.
    Park, Y. H.
    Hegg, R.
    Kim, M. H.
    Tseng, L-M.
    Petry, V.
    Chung, C-F.
    Iwata, H.
    Hamilton, E.
    Curigliano, G.
    Xu, B.
    Lee, C.
    Liu, Y.
    Cathcart, J.
    Bako, E.
    Verma, S.
    Hurvitz, S. A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1287 - S1288
  • [50] Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer
    Krop, Ian E.
    Modi, Shanu
    LoRusso, Patricia M.
    Pegram, Mark
    Guardino, Ellie
    Althaus, Betsy
    Lu, Dan
    Strasak, Alexander
    Elias, Anthony
    BREAST CANCER RESEARCH, 2016, 18
12345